Comparison between long acting insulin analogue and biphasic insulin aspart30/70 (BIAsp 30) as combination therapy with oral anti-diabetic agents.

Comparison between long acting insulin analogue and biphasic insulin aspart30/70 (BIAsp 30) as combination therapy with oral anti-diabetic agents. - Comparison between long acting insulin analogue and biphasic insulin aspart30/70 (BIAsp 30)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005194

Enrollment

Registered

2011-03-04

Start date

2009-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with type 2 diabetes mellitus

Interventions

Changing from long ancting insurlin analogue to BIAsp 30 without changing the dose of oral anti-diabetic agents. After 3 months of BIAsp 30 therapy, reconversion from BIAsp 30 to long ancting insurli

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients treated with BOT using long acting insulin analogues

Exclusion criteria

Exclusion criteria: Patients wiht severe liver or renal injury. Patients in the perioperative period.

Design outcomes

Primary

Measure	Time frame
The level of HbA1cand 1,5-AG. Mean value and coefficient of variance (CVs) obtained from SMBG	—

Secondary

Measure	Time frame
body weight and the frequency of hypoglycemia.	—

Countries

Japan

Contacts

Public ContactAtsuhito Tone

National Hospital Organization, Okayama Medical Center Department of Diabetes and Metabolism

aitone@okayama3.hosp.go.jp+81-86-294-9911

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026